Pharmacogenetic role of dopamine transporter (SLC6A3) variation on response to disulfiram treatment for cocaine addiction.

ABSTRACT:

Background and objectives

Disulfiram has been beneficial in treating cocaine addiction in several studies. Patients with two SLC6A3 (DAT1) rs28363170 10-repeat alleles who have with genetically high dopamine transporter (DAT) levels may benefit from increased dopamine levels resulting from disulfiram treatment.

Methods

After stabilization for 2 weeks on methadone, 70 cocaine and opioid codependent patients were randomized into disulfiram and placebo groups for 12 weeks of treatment. We genotyped the SLC6A3 (DAT1) 40 bp 3'-untranslated region variable number tandem repeat variant and evaluated its role in moderating disulfiram efficacy for cocaine dependence.

Results

Among the 10,10-repeat genotype group, cocaine-positive urines dropped from 78% to 48% and from 80% to

SUBMITTER: Kampangkaew JP 

PROVIDER: S-EPMC6591035 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature